Glenmark Pharmaceuticals Recalls Chlorpromazine Hydrochloride Tablets Over Nitrosamine Impurity
Glenmark Pharmaceuticals Inc., USA initiated a Class II recall of 8,160 bottles of Chlorpromazine Hydrochloride Tablets, USP 100 mg, due to N-Nitroso-Desmethyl Chlorpromazine impurity exceeding interim limits. This voluntary recall, stemming from CGMP deviations, impacts nationwide U.S. and Puerto Rico distribution. Procurement and regulatory teams must assess supply chain stability and evaluate alternative generic antipsychotic sources to mitigate disruption.
FDA-Mandated Class II Recall: Glenmark's Chlorpromazine Hydrochloride Impurity
Glenmark Pharmaceuticals Inc., USA has initiated a voluntary, firm-initiated Class II recall, D-0309-2025, for specific lots of its Chlorpromazine Hydrochloride Tablets, USP 100 mg. This critical action, commenced on March 11, 2025, addresses Current Good Manufacturing Practice (CGMP) deviations, specifically the detection of N-Nitroso-Desmethyl Chlorpromazine impurity at levels surpassing the recommended interim limit. For procurement directors and regulatory affairs heads, this signifies an immediate supply disruption for a critical antipsychotic medication. The Class II classification indicates that the product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. This necessitates prompt action to quarantine affected stock and assess patient impact. The recall encompasses 8,160 bottles of the 100 mg strength, distributed nationwide across the USA and Puerto Rico. The affected lots are 17232222 and 17232237, both with an expiration date of October 31, 2025. The product, identified by NDC 68462-864-01, is manufactured for Glenmark Pharmaceuticals Inc., USA, located in Mahwah, NJ, but notably, the product itself is designated as "Product of India." This dual origin highlights the complexities of global pharmaceutical supply chains and the need for rigorous oversight of contract manufacturing organizations (CMOs) or internal facilities abroad. Business development executives must recognize that such impurity-driven recalls can erode market confidence and necessitate significant investment in quality control enhancements to regain trust and market share.
Glenmark's Operational Footprint and Chlorpromazine HCl Sourcing
While Glenmark Pharmaceuticals Inc., USA, based in Mahwah, NJ 07430-2009, is the recalling firm and market authorization holder for Chlorpromazine Hydrochloride Tablets, USP 100 mg (ANDA212144), the product itself is explicitly stated as a "Product of India." This indicates that the manufacturing of the finished dosage form, or potentially the active pharmaceutical ingredient (API), occurs in India, with Glenmark's U.S. entity responsible for distribution and regulatory compliance within the U.S. market. For supply chain VPs, this distinction is crucial: it means that the CGMP deviations leading to the N-Nitroso-Desmethyl Chlorpromazine impurity likely originated at an overseas manufacturing site, rather than Glenmark's U.S. commercial operations. The recall of 8,160 bottles of Chlorpromazine Hydrochloride Tablets, a widely used phenothiazine antipsychotic, underscores the vulnerability inherent in geographically dispersed supply chains. Procurement directors must understand that while the U.S. entity bears the recall burden, the root cause investigation will invariably extend to the Indian manufacturing site. This necessitates a deep dive into the quality management systems and impurity control strategies of their overseas partners. The incident reinforces the imperative for robust vendor qualification programs that include regular audits of foreign manufacturing facilities, particularly for products with a history of nitrosamine impurity concerns. Failure to adequately vet and monitor these international sites can lead to significant business continuity risks and regulatory penalties for the U.S. market authorization holder.
Mitigating Supply Chain Disruption for Chlorpromazine Hydrochloride
The Class II recall of Glenmark Pharmaceuticals' Chlorpromazine Hydrochloride Tablets, USP 100 mg, due to N-Nitroso-Desmethyl Chlorpromazine impurity, presents immediate supply chain challenges for healthcare providers and pharmacies nationwide in the USA and Puerto Rico. With 8,160 bottles removed from circulation, purchasers of this specific generic formulation face a sudden reduction in available stock. For procurement directors, this necessitates an urgent assessment of current inventory levels and the identification of alternative suppliers to prevent potential drug shortages. Chlorpromazine Hydrochloride is a foundational medication for managing psychotic disorders, and any disruption can have significant clinical consequences, impacting patient care and potentially leading to increased healthcare costs if more expensive alternatives are required. Regulatory affairs heads must guide their organizations in understanding the implications of nitrosamine impurities, which have been a significant focus of global regulators, including the FDA, in recent years. The presence of N-Nitroso-Desmethyl Chlorpromazine above interim limits indicates a failure in process control or raw material quality, requiring a thorough investigation and corrective actions. This event highlights the broader industry-wide challenge of controlling these genotoxic impurities. Business development executives should view this as an opportunity to differentiate their products through superior quality control and transparency, especially in the competitive generic pharmaceutical market. Proactive communication with customers regarding supply status and mitigation strategies is paramount to maintaining trust and market share in the wake of such a recall.
Strategic Sourcing: Identifying Alternative Chlorpromazine Hydrochloride Suppliers
Given the Class II recall of Glenmark Pharmaceuticals' Chlorpromazine Hydrochloride Tablets, procurement teams must immediately evaluate alternative sources to ensure continuity of supply for this essential antipsychotic medication. While specific alternative suppliers are not detailed in the provided intelligence, the generic nature of Chlorpromazine Hydrochloride (ANDA212144) suggests that other manufacturers hold FDA approvals for this molecule. Strategic sourcing initiatives should prioritize suppliers with a demonstrated history of robust quality management systems and a clear track record of compliance with CGMP regulations, particularly concerning nitrosamine impurity control. This involves reviewing FDA inspection databases, assessing supplier audit reports, and verifying product quality documentation. For supply chain VPs, this incident underscores the critical importance of supply chain diversification. Relying on a single source or a limited number of suppliers, especially for generic medications where price competition is fierce, can expose organizations to significant risk during unforeseen quality events. Developing a multi-source strategy, including pre-qualified alternative manufacturers, is no longer a luxury but a necessity. Qualification timelines for new suppliers can be extensive, often requiring several months for full due diligence, analytical testing, and regulatory documentation. Therefore, proactive identification and qualification of backup suppliers should be an ongoing process, not a reactive measure. This recall serves as a stark reminder that the lowest price does not always equate to the lowest total cost when factoring in potential supply disruptions and reputational damage.
Evolving Regulatory Landscape: Nitrosamine Impurities and CGMP Compliance
While specific prior regulatory actions against Glenmark Pharmaceuticals Inc., USA, are not detailed in the available intelligence, this Class II recall of Chlorpromazine Hydrochloride Tablets due to N-Nitroso-Desmethyl Chlorpromazine impurity highlights a broader, industry-wide focus by regulatory bodies like the FDA on product quality and safety. The detection of nitrosamine impurities has been a pervasive issue across various drug classes since 2018, prompting extensive guidance from the FDA and other global health authorities. This recall underscores that despite ongoing efforts, controlling these genotoxic impurities remains a significant challenge for pharmaceutical manufacturers. For regulatory affairs heads, this means continuous vigilance and adaptation to evolving regulatory expectations regarding impurity profiles and analytical testing methodologies. The CGMP deviations cited as the reason for this recall are a fundamental concern for the FDA. CGMP compliance is the bedrock of pharmaceutical manufacturing quality, ensuring products meet identity, strength, quality, and purity standards. Failures in CGMP, whether related to process control, raw material qualification, or analytical testing, can lead to serious product quality issues, as demonstrated by this recall. The broader regulatory environment is characterized by heightened scrutiny, as evidenced by events such as the FDA Class II Recall of Essential Wellness Pharma's Progesterone Injection in June 2026 for sterility failures, or the FDA hearing concerning Amgen's Tavneos market future. These parallel events indicate a sustained regulatory pressure on pharmaceutical companies to uphold stringent quality standards across all aspects of manufacturing and product lifecycle management.
Post-Recall Remediation and Future Regulatory Scrutiny for Glenmark
Following the voluntary Class II recall of Chlorpromazine Hydrochloride Tablets, Glenmark Pharmaceuticals Inc., USA, is now obligated to conduct a thorough root cause analysis for the presence of N-Nitroso-Desmethyl Chlorpromazine impurity and the underlying CGMP deviations. This analysis must identify precisely how the impurity formed or was introduced and detail the corrective and preventive actions (CAPAs) to prevent recurrence. For regulatory affairs and quality assurance teams, this involves a comprehensive review of manufacturing processes, raw material specifications, supplier qualification, and analytical testing methods. The FDA will closely monitor Glenmark's remediation efforts, and inadequate responses could escalate to further regulatory actions, including potential Warning Letters, import alerts for the manufacturing facility in India, or even consent decrees. Supply chain VPs and procurement directors should anticipate potential delays in the reintroduction of Glenmark's Chlorpromazine Hydrochloride Tablets to the market until the FDA is satisfied with the implemented CAPAs. This period of uncertainty necessitates maintaining diversified sourcing strategies. The "Ongoing" status of the recall, initiated on March 11, 2025, with a center classification date of April 2, 2025, indicates that the process of identifying and removing affected product from distribution channels is still active. Business development executives should prepare for potential market share shifts as customers seek more stable supply options. This incident serves as a critical reminder that robust quality systems and proactive impurity control are not merely compliance requirements but essential components of long-term business sustainability and market competitiveness in the global pharmaceutical industry.